Drug Approval | May 03, 2025
USFDA inspection at Concord Biotech’s API facility at Dholka
These observations are procedural in nature and none of them are related to data integrity
These observations are procedural in nature and none of them are related to data integrity
The Board has also approved plans to invest approximately Rs. 500 crores including cost of land in developing a state-of-the-art, 400-bed super specialty hospital
Delivers robust earnings performance, successfully navigating a dynamic environment
The closing of the Block Acquisition is now expected to be completed by Q3 2025
Akums and TNAU will collaborate to strengthen research through shared expertise and innovative agricultural solutions, to foster innovation in formulation development
The implementation, spearheaded by Deloitte Consulting, brings together domain expertise and cutting-edge technology
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
A new weapon in the global fight against malaria
The newly inaugurated facility bridges this gap by offering metro-grade treatment closer to home
Subscribe To Our Newsletter & Stay Updated
